# Hepatology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ernest Hemingway (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET003-SYN-TD
- Date: 1955-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ingrid Solheim, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Walter Brandt-Ochoa, MD

## Reason for consultation

Raised transferrin saturation and ferritin with raised liver enzymes in a 55-year-old man with severe alcohol use disorder. Please advise on the cause, whether and how to stage his liver, and treatment. **S**

## History

Mr. Hemingway, a 55-year-old writer, is seen at the request of Dr. Brandt-Ochoa. He has drunk heavily for many years and has cut down from about ten drinks a day to five or six in the two weeks since he started naltrexone. A year ago, in two plane crashes, he had a concussion with a skull fracture and injuries to his right kidney, liver and spleen; he was not told of any lasting liver damage. He has no jaundice, abdominal swelling, bleeding, confusion or joint pain in his hands. He takes no iron, vitamin C or other supplements and eats raw oysters now and then. He has not been told of hemochromatosis in his family. **S**

## Examination

| System | Finding |
|---|---|
| General | Well; no smell of alcohol; blood pressure 144/90 |
| Abdomen | Liver edge 1 cm below the costal margin, smooth and non-tender; no spleen felt; no ascites |
| Skin | No jaundice, spider naevi, palmar erythema or bronze pigmentation |
| Musculoskeletal | No swelling or tenderness of the second and third knuckles |

BP 144/90 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 97.4 kg; BMI 29.1 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Brandt-Ochoa's intake note and today's two-week note. HFE genotype: C282Y homozygous. Intake: transferrin saturation 76%, serum iron 214 ug/dL, ferritin 1,460 ng/mL; AST 70, ALT 78 and GGT 196 U/L; bilirubin 1.0 mg/dL; albumin 4.1 g/dL; platelets 208; MCV 102 fL; HbA1c 6.1%; HIV, hepatitis B and hepatitis C nonreactive. Today: ferritin 1,395 ng/mL; AST 58, ALT 66 and GGT 160 U/L. Transient elastography in clinic today: liver stiffness 9.4 kPa, controlled attenuation parameter 288 dB/m. AST: 58 U/L (high); ALT: 66 U/L (high); GGT: 160 U/L (high); Ferritin: 1395 ng/mL (high); Liver stiffness (transient elastography): 9.4 kPa (high). All results are synthetic.

## Assessment

1. **Hereditary hemochromatosis, C282Y homozygous** (E83.110). C282Y homozygosity with a transferrin saturation over 45% and a raised ferritin confirms HFE hemochromatosis. Alcohol raises ferritin and adds liver injury, but with this genotype and a saturation of 76% most of the iron excess is genetic; the liver iron concentration on MRI will show the size of the load. His heavy drinking multiplies the risk of cirrhosis from iron. **S**
2. **Liver staging** (E83.110). A ferritin over 1,000 ng/mL with a raised ALT means a higher risk of advanced fibrosis, so staging is needed. Today's stiffness of 9.4 kPa is indeterminate and may be raised by recent drinking and inflammation. An MRI with R2* liver iron quantification and magnetic resonance elastography can stage the liver without a biopsy, as the ACG guideline allows; a biopsy would be considered only if the MRI suggested advanced fibrosis or another cause. **S**
3. **Alcohol and the liver** (F10.20). Naltrexone is reasonable: his aminotransferases are under three times the upper limit, he has no acute hepatitis or liver failure, and his liver tests have already fallen. Repeat them at about one month and then every few months. For his liver the safest amount of alcohol is none, at least while iron is being removed; he has chosen to keep cutting down first, and that choice should be respected and revisited. **S**
4. **Liver cancer surveillance, relatives and diet**. Surveillance for liver cancer every six months is needed only if he has cirrhosis or advanced fibrosis, which the MRI will decide. His first-degree relatives (siblings and adult children) should be offered transferrin saturation, ferritin and HFE testing; he may share a letter as he chooses. He should avoid iron and vitamin C supplements and raw shellfish, because iron overload greatly raises the risk of severe Vibrio infection; ordinary food needs no iron restriction. **S**

## Recommendations

1. Weekly phlebotomy of 500 mL, as tolerated, with a hemoglobin check before each session; hold if hemoglobin falls below 12.0 g/dL.
2. Ferritin about every ten to twelve sessions, then more often as it nears the target of 50 to 100 ng/mL; then maintenance phlebotomy to keep ferritin 50 to 100 ng/mL.
3. MRI of the liver with R2* iron quantification and magnetic resonance elastography within four weeks; liver biopsy only if it suggests advanced fibrosis or another cause.
4. Liver cancer surveillance only if the MRI shows advanced fibrosis or cirrhosis.
5. Continue naltrexone with liver tests at about one month and then every three to six months; no alcohol is best for the liver, and his own goal should be revisited when the MRI is back.
6. No iron or vitamin C supplements and no raw shellfish; keep wounds out of seawater.
7. Offer testing to first-degree relatives through a letter he may share; record no relative's result in his chart.
8. Check HbA1c and joints over time, and consider an echocardiogram for the heart, because iron overload can affect the pancreas, joints and heart.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Brandt-Ochoa, who sees him the same day. The plan was explained to Mr. Hemingway, who agreed to weekly phlebotomy and the MRI and asked to decide about stopping alcohol when he has the MRI result. **S**

## Follow-up

Hepatology will review the MRI report and send advice to Dr. Brandt-Ochoa, with a clinic review sooner if it shows advanced fibrosis; review in clinic when ferritin reaches the target. Dr. Brandt-Ochoa manages phlebotomy, alcohol treatment and monitoring in between. **S**

## Guideline basis

- Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases (2011), American Association for the Study of Liver Diseases (Hepatology 2011;54(1):328-343)
- ACG Clinical Guideline: Hereditary Hemochromatosis (2019), American College of Gastroenterology (Am J Gastroenterol 2019;114(8):1202-1218)
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
